Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

ملخص الخبر

ORZEYFULTM approved in the U.S., Japan and China for narcolepsy type 1 (NT1), MIMRYLOTM launched in the U.S. for erythrocytosis in polycythemia vera (PV) Zasocitinib advances to U.S.